BioNexus Gene Lab Corp
NASDAQ:BGLC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (12.4), the stock would be worth $-15.91 (868% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.6 | $2.07 |
0%
|
| Industry Average | 12.4 | $-15.91 |
-868%
|
| Country Average | 15.5 | $-19.86 |
-1 060%
|
Forward P/E
Today’s price vs future net income
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| MY |
|
BioNexus Gene Lab Corp
NASDAQ:BGLC
|
3.7m USD | -1.6 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
292.6B USD | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
100.8B ZAR | 10.4 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.3B USD | 38 034.1 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
53B USD | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
37.1B CHF | 0 | |
| US |
|
Coupang Inc
F:788
|
31.4B EUR | 175.7 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
34.4B USD | -3 154.1 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
29.6B ZAR | 6.8 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 10.9 |
| Median | 15.5 |
| 70th Percentile | 23.6 |
| Max | 227 361.7 |
Other Multiples
BioNexus Gene Lab Corp
Glance View
BioNexus Gene Lab Corp. is a molecular diagnostics company, which focuses on the application of functional genomics to enable diagnosis and personalized health management. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan and currently employs 8 full-time employees. The company went IPO on 2020-03-11. The firm is focused on the application of functional genomics to enable early diagnosis and personalized health management. The firm's wholly owned subsidiaries include Bionexus Gene Lab Sdn. Bhd. (Bionexus Malaysia) and Chemrex Sdn. Bhd. (Chemrex). BioNexus Malaysia owns algorithm software, technology and know-how related to the detection of common diseases through blood analysis which it uses in its business. Its non-invasive blood screening tests analyze changes in ribonucleic acid (RNA) to detect the risk potentiality of approximately 11 different diseases. These diseases include cancers, bowel diseases and osteoarthritis. Chemrex is a wholesaler of industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical and electronic industries in Asia Pacific region.
